Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCS1477 in advanced solid or metastatic tumors
NL-OMON51947Phase 2Active, not recruiting
- Sponsor
- CellCentric
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inobrodib in Nonhematologic neoplasms, prostate cancer (PCa), breast cancer and 1 more (14 arms), sponsored by CellCentric. Primary endpoint: Safety and tolerability of CCS1477 as monotherapy and in combination. Started Mar 2022; status: active, not recruiting.
02
Drugs
inobrodib
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON51947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51947.